<!DOCTYPE html>

<html lang="en">
  <head>
    <meta charset="utf-8" />
    <meta content="IE=edge" http-equiv="X-UA-Compatible" />
    <meta content="width=device-width, initial-scale=1.0" name="viewport" />
    <title>GA TB Reference Guide</title>
    <meta content="GA TB Reference Guide" name="description" />
    <meta content="SitePoint" name="author" />
    <link href="../assets/uikit.css" rel="stylesheet" />
    <link href="../assets/style.css" rel="stylesheet" />
  </head>

  <body>
    <div class="uk-container">
      <div class="chapter-header">
        <div class="header-title">
          <div>
            <img
              src="ic_chart.svg"
              width="16"
              height="16"
              class="ic_chapter_icon"
            />
          </div>
          <p class="chapter-title">
            2. Interpretation Criteria for the T-SPOT.TB Test
          </p>
        </div>
        <p>
          <span class="view-in-chapter-highlight">
            View in chapter →
            <span>
              <a
                href="2_diagnostic_tests_for_latent_tb_infection_(ltbi)__e__interferon_y_release_assays_(igras).html#table2"
              >
                Interferon-y Release Assays (IGRAs)
              </a></span>
          </span>
        </p>
        <p class="last-updated"><i>Last Updated October 2025</i></p>
      </div>
      <hr />
       <div class="uk-overflow-auto" id="table_2_interpretation_criteria_for_the_t_spot_tb_test">
        <div class="uk-tabs-container">
            <ul class="tabs">
                <li><button class="tab active-tab" onclick="switchTab(0, event)">Positive¹</button></li>
                <li><button class="tab" onclick="switchTab(1, event)">Borderline²</button></li>
                <li><button class="tab" onclick="switchTab(2, event)">Negative³</button></li>
                <li><button class="tab" onclick="switchTab(3, event)">Invalid⁴</button></li>
            </ul>
        </div>

        <table id="option-content0" class="uk-table tab-content option-content active-option">
            <tbody>
                <tr>
                    <th colspan="1">Nil
                        <span class="info-icon" data-tooltip="NOTE: The number of spots resulting from incubation of PBMCs in culture media without antigens." data-tooltip-position="tooltip-right">i</span></th>
                    <td colspan="1">&le; 10 spots</td>
                </tr>
                <tr>
                    <th colspan="1">TB Response
                        <span class="info-icon" data-tooltip="NOTE: The greater number of spots resulting from stimulation of peripheral blood mononuclear cells (PBMCs) with two separate cocktails of peptides representing early secretory antigenic target-6 (ESAT-6) or culture filtrate protein-10 (CFP-10) minus Nil." data-tooltip-position="tooltip-right">i</span></th>
                    </th>
                    <td colspan="1">&ge; 8 spots</td>
                </tr>
                <tr>
                    <th colspan="1">Mitogen
                        <span class="info-icon" data-tooltip="NOTE: The number of spots resulting from stimulation of PBMCs with mitogen without adjustment for the number of spots resulting from incubation of PBMCs without antigens." data-tooltip-position="tooltip-right">i</span>
                    </th>
                    <td colspan="1">Any</td>
                </tr>
            </tbody>
        </table>

        <table id="option-content1" class="uk-table tab-content option-content">
            <tbody>
                <tr>
                    <th colspan="1">Nil
                        <span class="info-icon" data-tooltip="NOTE: The number of spots resulting from incubation of PBMCs in culture media without antigens." data-tooltip-position="tooltip-right">i</span>
                    </th>
                    <td colspan="1">&lt; 10 spots</td>
                </tr>
                <tr>
                    <th colspan="1">TB Response
                        <span class="info-icon" data-tooltip="NOTE: The greater number of spots resulting from stimulation of peripheral blood mononuclear cells (PBMCs) with two separate cocktails of peptides representing early secretory antigenic target-6 (ESAT-6) or culture filtrate protein-10 (CFP-10) minus Nil." data-tooltip-position="tooltip-right">i</span>
                    </th>
                    <td colspan="1">5, 6, or 7 spots</td>
                </tr>
                <tr>
                    <th colspan="1">Mitogen
                        <span class="info-icon" data-tooltip="NOTE: The number of spots resulting from stimulation of PBMCs with mitogen without adjustment for the number of spots resulting from incubation of PBMCs without antigens." data-tooltip-position="tooltip-right">i</span>
                    </th>
                    <td colspan="1">Any</td>
                </tr>
            </tbody>
        </table>

        <table id="option-content2" class="uk-table tab-content option-content">
            <tbody>
                <tr>
                    <th colspan="1">Nil
                        <span class="info-icon" data-tooltip="NOTE: The number of spots resulting from incubation of PBMCs in culture media without antigens." data-tooltip-position="tooltip-right">i</span>
                    </th>
                    <td colspan="1">&le; 10 spots</td>
                </tr>
                <tr>
                    <th colspan="1">TB Response
                        <span class="info-icon" data-tooltip="NOTE: The greater number of spots resulting from stimulation of peripheral blood mononuclear cells (PBMCs) with two separate cocktails of peptides representing early secretory antigenic target-6 (ESAT-6) or culture filtrate protein-10 (CFP-10) minus Nil." data-tooltip-position="tooltip-right">i</span>
                    </th>
                    <td colspan="1">> 20 spots</td>
                </tr>
                <tr>
                    <th colspan="1">Mitogen
                        <span class="info-icon" data-tooltip="NOTE: The number of spots resulting from stimulation of PBMCs with mitogen without adjustment for the number of spots resulting from incubation of PBMCs without antigens." data-tooltip-position="tooltip-right">i</span>
                    </th>
                    <td colspan="1">> 20 spots</td>
                </tr>
            </tbody>
        </table>

        <table id="option-content3" class="uk-table tab-content option-content">
            <tbody>
                <tr>
                    <th colspan="1">Nil
                        <span class="info-icon" data-tooltip="NOTE: The number of spots resulting from incubation of PBMCs in culture media without antigens." data-tooltip-position="tooltip-right">i</span>
                    </th>
                    <td colspan="1">&le; 10 spots</td>
                    <td colspan="1">&le; 10 spots</td>
                </tr>
                <tr>
                    <th colspan="1">TB Response
                        <span class="info-icon" data-tooltip="NOTE: The greater number of spots resulting from stimulation of peripheral blood mononuclear cells (PBMCs) with two separate cocktails of peptides representing early secretory antigenic target-6 (ESAT-6) or culture filtrate protein-10 (CFP-10) minus Nil." data-tooltip-position="tooltip-right">i</span>
                    </th>
                    <td colspan="1">Any</td>
                    <td colspan="1">< 5 spots</td>
                </tr>
                <tr>
                    <th class="uk-table-small" colspan="1">Mitogen
                        <span class="info-icon" data-tooltip="NOTE: The number of spots resulting from stimulation of PBMCs with mitogen without adjustment for the number of spots resulting from incubation of PBMCs without antigens." data-tooltip-position="tooltip-right">i</span>
                    </th>
                    <td colspan="1">Any</td>
                    <td colspan="1">< 20 spots</td>
                </tr>
            </tbody>
        </table>
    </div>
      <p>
        Source: Based on Oxford Immunotec T-Spot.TB package insert. <br />
        Available at:
        <a
          href="http://www.oxfordimmunotec.com/international/wp-content/uploads/sites/3/Final-File-PI-TB-US-V6.pdf "
          class="res-width"
        >
          http://www.oxfordimmunotec.com/international/wp-content/uploads/sites/3/Final-File-PI-TB-US-V6.pdf
        </a>
      </p>
      <p>
        1. Interpretation indicating that Mycobacterium tuberculosis infection
        is likely. <br />
        2. Interpretation indicating an uncertain likelihood of M. tuberculosis
        infection. In the case of Invalid results, these should be reported as
        “Invalid” and it is recommended to collect another sample and retest the
        individual. <br />
        3. Interpretation indicating that M. tuberculosis infection is not
        likely.
      </p>
    </div>
  </body>

  <script src="../assets/uikit.js" type="text/javascript"></script>
  <script src="../assets/uikit-icons.js" type="text/javascript"></script>
  <script src="main.js" type="text/javascript"></script>
</html>
